Labcorp Holdings Inc.

Labcorp Holdings Inc. is a leading global life sciences company that provides comprehensive clinical laboratory services, diagnostic testing, and drug development solutions. Founded in 1971 and headquartered in Burlington, North Carolina, the company operates through two main segments: Labcorp Diagnostics and Labcorp Drug Development. Labcorp Diagnostics offers a broad range of routine and esoteric tests, including blood work, genetic testing, and pathology services, serving patients, physicians, hospitals, and health plans. Labcorp Drug Development supports pharmaceutical and biotechnology companies in clinical trial management, central laboratory services, and regulatory consulting, helping to accelerate the development of new therapies.

The company generates revenue primarily through fee-for-service testing and clinical trial support. In the Diagnostics segment, revenue comes from insurance reimbursements, patient payments, and contracts with healthcare providers. The Drug Development segment earns revenue through long-term contracts with biopharma clients, often on a milestone or cost-plus basis. For the latest fiscal year, total revenue reached approximately $14.1 billion, with roughly 60% from Diagnostics and 40% from Drug Development. Labcorp has a diversified revenue stream across geographies, with the majority from the United States, followed by Europe and Asia.

Labcorp operates in the highly competitive diagnostics and clinical research industry, facing rivals such as Quest Diagnostics, Eurofins Scientific, and IQVIA. The industry is characterized by consolidation, technological advancement, and regulatory complexity. Labcorp differentiates itself through its extensive test menu (over 5,000 tests), global laboratory network, and integrated drug development services. The company holds a strong position in the U.S. diagnostic market with approximately 25% market share and is a top-tier player in central laboratory services for clinical trials. Its scale and breadth allow it to serve both routine and specialized testing needs efficiently.

Labcorp's primary customers include patients, physicians, hospitals, health systems, health insurers, and biopharmaceutical companies. The company serves over 100 million patients annually through its network of more than 2,000 patient service centers and partnerships with major hospital systems. In drug development, it works with most of the top 20 global biopharma companies. Geographically, the U.S. accounts for about 80% of revenue, with significant operations in Europe (especially the UK, Germany, and Switzerland) and a growing presence in Asia-Pacific. The company's services are essential for disease diagnosis, health management, and new drug approvals, making it a critical partner in the healthcare ecosystem.

An auto-generated descriptive profile based on company data, for informational purposes only.